Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumour vascular-targeting and novel recombinant human tumour necrosis factor fusion protein and its preparation

A technology of tumor necrosis factor and fusion protein, which is applied in the fields of hybrid peptide, genetic engineering, plant gene improvement, etc., and can solve the problem of no obvious inhibition of natural tumor necrosis factor

Inactive Publication Date: 2003-03-26
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, tumor vascular cells are normal cells that enter the tumor from normal tissues, have a stable genome, and are not prone to multiple drug resistance like tumor cells
Anti-CD13 monoclonal antibody can significantly inhibit the tumor suppressor activity of CNGRC-TNF in vivo, making it reach the same level as natural tumor necrosis factor; but has no obvious inhibitory effect on natural tumor necrosis factor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumour vascular-targeting and novel recombinant human tumour necrosis factor fusion protein and its preparation
  • Tumour vascular-targeting and novel recombinant human tumour necrosis factor fusion protein and its preparation
  • Tumour vascular-targeting and novel recombinant human tumour necrosis factor fusion protein and its preparation

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0125] The applicant selected a cyclic peptide CGRDC containing five amino acids that can specifically bind to αvβ3 integrin, applied gene recombination method, fused it to the amino terminal of nrhTNF, and obtained expression in Escherichia coli. On the basis of successfully constructing and expressing the fusion gene, a low-cost purification process was established with reference to the purification method of nrhTNF. In the in vitro killing test, the fusion protein RGD-nrhTNF has a dose-dependent and obvious killing effect on L929 cells, and the specific activity reaches 5.7×10 8 IU / mg. In animal tumor models, the fusion protein RGD-nrhTNF has a significant inhibitory effect on mouse S180 ascites tumor (tumor inhibition rate is 84.84%), which is significantly higher than the same dose of nrhTNF (tumor inhibition rate is 59.09%). And the side effects are lower than nrhTNF. Although we have no direct evidence to prove that RGD-nrhTNF can enrich the new recombinant human tumo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
recovery rateaaaaaaaaaa
Login to View More

Abstract

A kind of amalgamation albumen combined peptide and hrn TNF specificity of the knub neconatal vein and its preparation method is disclosed in the invention. The knub necro-gene is a kind of multi-functional cell gene, which participates in immunity metabolizating modulation of the economy, has restriant and cell poison action to growth of some cancer cells. The invention wipes off 1-7 bit amino acid of the amido end of the knub necro-gene, changes 8-10 bit amino acid into Arg-Lys-Arg and 157 bit amino acid of carboxyl end into Phe, and composes new type high effect and low poison knub necro-gene nrhTNF. On the basis, prepared amalgamation albumen combined peptide and nrhTNF specificity ofthe knub neonatal vein can enrich at the place of knub neonated vein by use of the cyclopeptide CRGDC containing five amino acids elected from phage revelation library.

Description

[0001] 1. Field [0002] The invention belongs to the field of medical biotechnology, and specifically relates to gene cloning, gene mutation, expression of exogenous gene in prokaryotic cells, purification of target protein, tumor neovascularization-specific binding polypeptide and novel recombinant human tumor necrosis factor (nrhTNF) fusion protein In vivo and in vitro activity determination and identification of physical and chemical properties. It further relates to a tumor vascular-directing and novel recombinant human tumor necrosis factor fusion protein and its preparation, that is, a tumor neovascularization-specific binding polypeptide and a novel recombinant human tumor necrosis factor (nrhTNF) fusion protein and its preparation, which is specific for tumor neovascularization Sex-binding polypeptide and novel recombinant human tumor necrosis factor (nrhTNF) fusion protein are used as anti-tumor drugs, which can specifically act on neovascular endothelial cells and tum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/12
Inventor 张英起王慧颜真赵宁
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com